Free Trial

Calidi Biotherapeutics (CLDI) Competitors

Calidi Biotherapeutics logo
$0.73 -0.04 (-5.43%)
Closing price 04:00 PM Eastern
Extended Trading
$0.64 -0.10 (-13.01%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CLDI vs. VXRT, XBIT, OCX, VIRI, CNTB, MIST, BYSI, IPA, ZURA, and ORMP

Should you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Vaxart (VXRT), XBiotech (XBIT), OncoCyte (OCX), Virios Therapeutics (VIRI), Connect Biopharma (CNTB), Milestone Pharmaceuticals (MIST), BeyondSpring (BYSI), ImmunoPrecise Antibodies (IPA), Zura Bio (ZURA), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry.

Calidi Biotherapeutics vs. Its Competitors

Vaxart (NASDAQ:VXRT) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

18.0% of Vaxart shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 2.9% of Vaxart shares are owned by insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Calidi Biotherapeutics had 1 more articles in the media than Vaxart. MarketBeat recorded 3 mentions for Calidi Biotherapeutics and 2 mentions for Vaxart. Vaxart's average media sentiment score of 0.58 beat Calidi Biotherapeutics' score of 0.13 indicating that Vaxart is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxart
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Calidi Biotherapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Calidi Biotherapeutics has a net margin of 0.00% compared to Vaxart's net margin of -122.63%. Calidi Biotherapeutics' return on equity of 0.00% beat Vaxart's return on equity.

Company Net Margins Return on Equity Return on Assets
Vaxart-122.63% -91.89% -38.40%
Calidi Biotherapeutics N/A N/A -344.45%

Calidi Biotherapeutics has lower revenue, but higher earnings than Vaxart.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaxart$47.40M1.93-$66.95M-$0.27-1.48
Calidi BiotherapeuticsN/AN/A-$29.22MN/AN/A

Vaxart has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Vaxart presently has a consensus price target of $3.00, indicating a potential upside of 650.00%. Given Vaxart's stronger consensus rating and higher possible upside, research analysts plainly believe Vaxart is more favorable than Calidi Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxart
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Calidi Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Vaxart beats Calidi Biotherapeutics on 8 of the 13 factors compared between the two stocks.

Get Calidi Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLDI vs. The Competition

MetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$28.04M$272.87M$5.74B$21.13B
Dividend YieldN/AN/A4.60%3.58%
P/E RatioN/AN/A28.1127.87
Price / SalesN/A364.38461.3759.63
Price / CashN/A22.4436.5523.02
Price / Book-0.3112.418.654.69
Net Income-$29.22M-$106.40M$3.25B$995.51M
7 Day Performance22.98%4.86%4.20%1.64%
1 Month Performance217.94%25.43%10.82%5.92%
1 Year Performance-57.11%11.08%34.70%11.50%

Calidi Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLDI
Calidi Biotherapeutics
0.5592 of 5 stars
$0.73
-5.4%
N/A-53.8%$28.04MN/A0.0038Gap Down
VXRT
Vaxart
3.1579 of 5 stars
$0.40
+6.5%
$3.00
+655.1%
-39.3%$90.95M$47.40M-1.47120News Coverage
Gap Down
XBIT
XBiotech
1.6343 of 5 stars
$2.98
+8.4%
N/A-55.0%$90.85MN/A-2.31100Positive News
OCX
OncoCyte
1.2348 of 5 stars
$3.18
+16.3%
$6.06
+90.9%
-1.1%$90.80M$3.84M-0.90120
VIRI
Virios Therapeutics
N/A$4.70
-7.5%
$5.00
+6.4%
+1,990.2%$90.51MN/A-17.415
CNTB
Connect Biopharma
2.8479 of 5 stars
$1.62
+11.0%
$7.00
+332.1%
+74.1%$90.01M$26.03M0.00110Analyst Upgrade
Analyst Revision
High Trading Volume
MIST
Milestone Pharmaceuticals
2.8103 of 5 stars
$1.67
+12.8%
$7.00
+319.2%
+6.1%$89.28M$1M-2.1430High Trading Volume
BYSI
BeyondSpring
N/A$2.21
-4.3%
N/A+2.1%$89.10MN/A0.0080Positive News
IPA
ImmunoPrecise Antibodies
3.028 of 5 stars
$1.93
+6.0%
$4.00
+107.3%
+164.6%$88.32M$18.16M-1.6680News Coverage
Upcoming Earnings
Gap Up
ZURA
Zura Bio
3.1063 of 5 stars
$1.29
-0.8%
$14.33
+1,011.1%
-54.6%$88.20MN/A-1.843
ORMP
Oramed Pharmaceuticals
1.1278 of 5 stars
$2.11
+1.0%
N/A-13.2%$86.19M$2M-4.8010News Coverage
Positive News

Related Companies and Tools


This page (NYSE:CLDI) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners